



## OPEN ACCESS

## EDITED AND REVIEWED BY

Jianping Chen,  
The Fourth Clinical Medical College of  
Guangzhou University of Chinese Medicine,  
China

## \*CORRESPONDENCE

Yi-Gang Wan,  
✉ wyg68918@sina.com  
Guo-Wen Wu,  
✉ jl-wgw@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

<sup>†</sup>These authors have contributed equally to this work and share last authorship

RECEIVED 10 June 2024

ACCEPTED 25 June 2024

PUBLISHED 23 July 2024

## CITATION

Liu B-H, Chong F-L, Yuan C-C, Liu Y-L, Yang H-M, Wang W-W, Fang Q-J, Wu W, Wang M-Z, Tu Y, Wan Z-Y, Wan Y-G and Wu G-W (2024), Corrigendum: Fucoidan ameliorates renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD-MBD model rats by targeting FGF23-Klotho signaling axis. *Front. Pharmacol.* 15:1446609. doi: 10.3389/fphar.2024.1446609

## COPYRIGHT

© 2024 Liu, Chong, Yuan, Liu, Yang, Wang, Fang, Wu, Wang, Tu, Wan, Wan and Wu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Fucoidan ameliorates renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD-MBD model rats by targeting FGF23-Klotho signaling axis

Bu-Hui Liu<sup>1,2†</sup>, Fee-Lan Chong<sup>3†</sup>, Can-Can Yuan<sup>1†</sup>, Ying-Lu Liu<sup>4</sup>, Hai-Ming Yang<sup>4</sup>, Wen-Wen Wang<sup>1</sup>, Qi-Jun Fang<sup>1</sup>, Wei Wu<sup>4</sup>, Mei-Zi Wang<sup>1</sup>, Yue Tu<sup>5</sup>, Zi-Yue Wan<sup>6</sup>, Yi-Gang Wan<sup>4\*\*</sup> and Guo-Wen Wu<sup>7\*\*†</sup>

<sup>1</sup>Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, <sup>2</sup>Nephrology Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China, <sup>3</sup>The School of Pharmacy, Management and Science University, Shah Alam, Malaysia, <sup>4</sup>Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, <sup>5</sup>Department of Traditional Chinese Medicine Health Preservation, Acupuncture, Moxibustion and Massage College, Health Preservation and Rehabilitation College, Nanjing University of Chinese Medicine, Nanjing, China, <sup>6</sup>Department of Social Work, Meiji Gakuin University, Tokyo, Japan, <sup>7</sup>Jilin Province Huinan Chonglong Bio-Pharmacy Co., Ltd., Huinan, China

## KEYWORDS

fucoidan, chronic kidney disease-mineral and bone disorder, FGF23-klotho signaling axis, phosphorus reabsorption, ERK1/2-SGK1-NHERF-1-NaPi-2a pathway


## A Corrigendum on

[Fucoidan ameliorates renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD-MBD model rats by targeting FGF23-Klotho signaling axis](#)

by Liu B-H, Chong F-L, Yuan C-C, Liu Y-L, Yang H-M, Wang W-W, Fang Q-J, Wu W, Wang M-Z, Tu Y, Wan Z-Y, Wan Y-G and Wu G-W (2021). *Front. Pharmacol.* 11:586725. doi: 10.3389/fphar.2020.586725

In the published article, there was an error in [Figure 5](#) as published. One image was erroneously overlapped in [Figure 5A](#) -FGF23-Sham + Vehicle, and in [Figure 5A](#) -FGF23-CKD-MBD + CTR. The corrected [Figure 5](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



**FIGURE 5** FPS and CTR regulated FGF23-Klotho signaling axis in vivo (A) The protein expression characteristics of Klotho, FGF23 and FGFR1 in renal tubulointerstitium of the kidneys in the four group rats. IHC staining  $\times 200$ . Scale bar  $100 \mu\text{m}$  (B) The protein expression levels of Klotho, FGF23 and FGFR1 in the kidney of the four group rats (C) The rate of Klotho/GAPDH (D) The rate of FGF23/GAPDH (E) The rate of FGFR1/GAPDH. The data are expressed as mean  $\pm$  S.D.  $**p < 0.01$ .

### Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.